- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05316155
국소 방광암에 대한 Erdafitinib 방광내 전달 시스템 연구
비근육 침습성 또는 근육 침습성 방광암 및 선별된 FGFR 돌연변이 또는 융합이 있는 참가자를 대상으로 한 Erdafitinib 방광내 전달 시스템(TAR-210)의 1상 연구
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
연구 개요
상세 설명
Bladder cancer is one of the most common malignancy worldwide, and non-muscle invasive (NMIBC) requires intensive regimens of frequent monitoring and local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-muscle invasive or muscle invasive bladder cancer with activating fibroblast growth factor receptor (FGFR) mutations or fusions. Erdafitinib is a pan-FGFR inhibitor with demonstrated clinical activity when administered orally in patients with solid tumors, including bladder cancer, with FGFR genetic alterations. The Erdafitinib intravesical delivery system is designed to provide release of Erdafitinib in the bladder to treat localized bladder cancer, while reducing systemic toxicities. The study consists of a screening phase, a treatment phase, and a follow-up phase. Total duration of the study is approximately up to 7 years 4 months.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
-
Nijmegen, 네덜란드, 6525 GA
- Radboud Umcn
-
Utrecht, 네덜란드, 3584 CX
- UMC Utrecht
-
-
-
-
-
Goyang-si, 대한민국, 10408
- National Cancer Center
-
Gwangju, 대한민국, 61469
- Chonnam National University Hospital
-
Seoul, 대한민국, 03080
- Seoul National University Hospital
-
Seoul, 대한민국, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, 대한민국, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Dresden, 독일, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg, 독일, 47169
- Urologicum Duisburg
-
Frankfurt am Main, 독일, 60590
- Universitatsklinikum Frankfurt
-
Herne, 독일, 44625
- Marien hospital Herne
-
Mettmann, 독일, 40822
- Urologie Neandertal Praxis Mettmann
-
Münster, 독일, 48149
- Universitatsklinikum Munster
-
Ulm, 독일, 89081
- Universitaetsklinikum Ulm
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- University of Alabama at Birmingham - The Kirklin Clinic
-
-
California
-
Los Angeles, California, 미국, 90033
- University of Southern California
-
-
Colorado
-
Lone Tree, Colorado, 미국, 80124
- Urology Associates of Denver
-
-
Florida
-
Hialeah, Florida, 미국, 33016
- Urological Research Network
-
Largo, Florida, 미국, 33771
- Advanced Urology Institute
-
Orlando, Florida, 미국, 32804
- Advent Health Orlando
-
Oxford, Florida, 미국, 34484
- Advanced Urology Institute 1
-
Tampa, Florida, 미국, 33612
- H Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern University
-
Chicago Ridge, Illinois, 미국, 60415
- Associated Urological Specialists
-
-
Indiana
-
Greenwood, Indiana, 미국, 46143
- Urology of Indiana
-
Merrillville, Indiana, 미국, 46410
- Urologic Specialists of Northwest Indiana
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40506
- University of Kentucky
-
-
Louisiana
-
Lafayette, Louisiana, 미국, 70508
- Southern Urology LLC
-
-
Massachusetts
-
Plymouth, Massachusetts, 미국, 02360
- Greater Boston Urology
-
-
Missouri
-
St Louis, Missouri, 미국, 63141
- Specialty Clinical Research of St Louis
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- Hackensack University Medical Center Urology
-
-
New York
-
Syracuse, New York, 미국, 13210
- Associated Medical Professionals
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- Levine Cancer Institute, Carolinas HealthCare System
-
-
Ohio
-
Gahanna, Ohio, 미국, 43230
- Central Ohio Urology Group
-
-
South Carolina
-
Myrtle Beach, South Carolina, 미국, 29572
- Carolina Urologic Research Center
-
North Charleston, South Carolina, 미국, 29406
- Low Country Urology Clinics
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37209
- Urology Associates
-
-
Texas
-
Austin, Texas, 미국, 78745
- Urology Austin
-
San Antonio, Texas, 미국, 78229
- Urology San Antonio Research
-
-
-
-
-
Barcelona, 스페인, 08025
- Fund. Puigvert
-
Barcelona, 스페인, 08036
- Hosp Clinic de Barcelona
-
Barcelona, 스페인, 08035
- Hosp Univ Vall D Hebron
-
Córdoba, 스페인, 14004
- Hosp Reina Sofia
-
Madrid, 스페인, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, 스페인, 28046
- Hosp. Univ. La Paz
-
Madrid, 스페인, 28040
- Hosp Univ Fund Jimenez Diaz
-
Valencia, 스페인, 46009
- Instituto Valenciano de Oncologia
-
-
-
-
-
Haifa, 이스라엘, 3109601
- Rambam Medical Center
-
Haifa, 이스라엘, 3436212
- Carmel Medical Center
-
Petah Tikva, 이스라엘, 4941492
- Rabin Medical Center
-
Tel Aviv, 이스라엘, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Fukuoka, 일본, 810 8563
- National Hospital Organization Kyushu Medical Center
-
Kofu, 일본, 400-8506
- Yamanashi Prefectural Central Hospital
-
Osaka, 일본, 558-8558
- Osaka General Medical Center
-
Toyama, 일본, 930 0194
- Toyama University Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Vancouver Prostate Centre Diamond Health Care Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 2Y9
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N 4A6
- St Josephs Healthcare Hamilton
-
Toronto, Ontario, 캐나다, M5G 2M9
- Princess Margaret Cancer Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Parts 1-3:
- Muscle-invasive or recurrent, non-muscle-invasive urothelial carcinoma of the bladder
- For selected Cohorts: Activating tumor pan-fibroblast growth factor receptor (FGFR) mutation or fusion, as determined by local or central testing, approved by the sponsor prior to the start of study treatment. Local tissue-based results (if already existing) from next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests performed in Clinical Laboratory Improvement Amendments (CLIA) -certified or equivalent laboratories, or results from commercially available PCR or NGS tests
- Cohorts 1 and 2: Bacillus Calmette-Guérin (BCG) experienced, or participants with no BCG experience because BCG was not available as a treatment option in the participant's location within the previous 2 years and is currently unavailable. Participants who received an abbreviated course of BCG due to toxicity are still eligible
- Cohort 1 only: Refuses or is not eligible for radical cystectomy (RC)
- Cohorts 2 and 4: Willing and eligible for RC
Part 4:
- Have histologically confirmed diagnosis of recurrent Intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC) Ta LG tumors
- Must not have undergone tumor debulking or selective ablation of visible lesions; partial tumor biopsy to confirm diagnosis and provide tissue for biomarker testing is permitted as long as remaining tumor is at least 5 millimeter (mm) in size
- Must submit tissue and urine for FGFR testing
- Can have a prior or concurrent second malignancy which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
Exclusion Criteria:
Parts 1-3:
- Concurrent extra-vesical (that is, urethra, ureter, renal pelvis) transitional cell carcinoma of the urothelium
- Prior treatment with an pan-fibroblast growth factor receptor (FGFR) inhibitor
- Received pelvic radiotherapy <=6 months prior to the planned start of study treatment. If received pelvic radiotherapy greater than (>)6 months prior to the start of study treatment, there must be no cystoscopic evidence of radiation cystitis
- Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe use of Erdafitinib intravesical delivery system
- Indwelling urinary catheter. Intermittent catheterization is acceptable
Part 4:
- Histologically confirmed diagnosis of T1 NMIBC, HR NMIBC (HG/G2 or HG/G3 or CIS) or MIBC, locally advanced, non-resectable, or metastatic urothelial carcinoma at any time prior to enrollment. Previous high grade (HG) disease is accepted as long as diagnosis date is greater than or equal to (>=5) years ago and there is documentation of low grade (LG) Ta thereafter
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients
- Has a current diagnosis of newly diagnosed IR-NMIBC
- Received an investigational treatment for bladder cancer after Transurethral Resection of the Bladder Tumor (TURBT) for the current NMIBC diagnosis or within 4 weeks or the agent/therapy washout period, whichever is longer, before the planned first dose of study treatment, or is currently enrolled in an investigational study
- Evidence of current bladder perforation by cystoscopy or imaging
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1: Dose Escalation
Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2. |
Erdafitinib intravesical delivery system will be administered.
다른 이름들:
|
|
실험적: Part 2: Dose Expansion
Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1. |
Erdafitinib intravesical delivery system will be administered.
다른 이름들:
|
|
실험적: Part 3: RP2D Dose Expansion
Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity. |
Erdafitinib intravesical delivery system will be administered.
다른 이름들:
|
|
실험적: Part 4: Phase 2 Expansion
Participants with recurrent IR-NMIBC will be enrolled in this part to further evaluate the safety, efficacy, and PK of the selected RP2D. |
Erdafitinib intravesical delivery system will be administered.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Parts 1 to 3: Number of Participants with Adverse Events (AEs)
기간: Up to approximately 7 years 4 months
|
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Number of Participants with AEs by Severity
기간: Up to approximately 7 years 4 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 7 years 4 months
|
|
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
기간: Up to 28 days
|
Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 28 days
|
|
Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
기간: Up to approximately 7 years 4 months
|
Overall CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy. |
Up to approximately 7 years 4 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Parts 1 to 3: Plasma Concentration of Erdafitinib
기간: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
Plasma concentration of Erdafitinib will be reported. |
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
|
Parts 1 to 3: Urine Concentration of Erdafitinib
기간: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
Urine concentration of Erdafitinib will be reported. |
Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
|
|
Parts 1 to 3: Cohorts 1 and 2: Recurrence-Free Survival (RFS)
기간: Up to approximately 7 years 4 months
|
RFS is defined as the time from start of treatment to the first detection of any new high-grade bladder cancer or upper tract urothelial carcinoma or positive urine cytology. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Cohort 3 and 5: Complete Response (CR) Rate
기간: At 3 months
|
CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology. |
At 3 months
|
|
Parts 1 to 3: Cohort 3 and 5: Duration of CR
기간: Up to approximately 7 years 4 months
|
Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first. |
Up to approximately 7 years 4 months
|
|
Parts 1 to 3: Cohort 4: Pathological Complete Response (pCR) Rate
기간: Up to 8 weeks
|
pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0). |
Up to 8 weeks
|
|
Parts 1 to 3: Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0)
기간: Up to 8 weeks
|
pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease. |
Up to 8 weeks
|
|
Parts 1 to 3: Cohort 4: Rate of downstaging to Less than (<) pT2
기간: Up to 8 weeks
|
Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2. |
Up to 8 weeks
|
|
Part 4: Duration of CR (DoCR) in Participants with IR-NMIBC
기간: Up to approximately 7 years 4 months
|
Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first. |
Up to approximately 7 years 4 months
|
|
Part 4: Complete Response (CR) at 3 Months in Participants with IR-NMIBC
기간: At Month 3
|
CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy at the first disease evaluation. |
At Month 3
|
|
Part 4: Transurethral Resection of the Bladder Tumor (TURBT)-Free Survival in Participants With IR-NMIBC
기간: Up to approximately 7 years 4 months
|
Participants with TURBT-free survival will be reported. |
Up to approximately 7 years 4 months
|
|
Part 4: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) by Severity
기간: Up to approximately 7 years 4 months
|
TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline. Severity was assessed using National cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity grades ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 7 years 4 months
|
|
Part 4: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Change from Baseline in European Organization for the Research and Treatment of Cancer Non-Muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC 24) Score
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-C30 Scores
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
|
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-NMIBC24 Scores
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR109115
- 42756493BLC1003 (기타 식별자: Janssen Research & Development, LLC)
- 2021-004144-22 (EudraCT 번호)
- 2023-506265-65-00 (레지스트리 식별자: EUCT number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .